Breast (Boost) Clinical Trials and Studies with IORT

Cancer Indication

Number of Patients

770

Summary/Conclusion

This study provides 10-year outcome data of 770 stage I through III breast cancer patients who received intraoperative electron radiation therapy (IOERT) as a tumor bed boost preceding whole breast irradiation. After a median follow-up period of 121 months, 21 in-breast recurrences (2.7%) occurred with triple-negative and HER2ﬂ subtypes as negative predictors. As confirmed in long-term follow-up, IOERT has been demonstrated to be a viable boost strategy in any risk constellation.

May 9, 2018

Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery

Treatment Use

Cancer Indication

Number of Patients

71

Summary/Conclusion

The purpose of this work was to retrospectively evaluate survival and local control rates of triple-negative breast cancer subtypes classified as five marker negative (5NP) and core basal (CB), respectively, after breast-conserving surgery and intraoperative boost radiotherapy with electrons (IOERT) followed by whole breast irradiation.

November 6, 2017

A prospective phase I comparison of toxicity and cosmesis outcomes of single-fraction IORT and hypofractionated radiotherapy with IORT boost in early-stage breast cancer

Treatment Use

Cancer Indication

Breast (Single-Fraction APBI)

Number of Patients

81

Summary/Conclusion

After breast conservation surgery, SF or HfB may be an option for patients with early-stage breast cancer compared to conventional external beam radiotherapy.

May 11, 2013

Fastner, G. et al., “IORT with Electrons as Boost Strategy During Breast Conserving Therapy in Limited Stage Breast Cancer: Long-term Results of an ISIORT Pooled Analysis.” (2013)

Treatment Use

Cancer Indication

Number of Patients

1109

Summary/Conclusion

In all risk groups, a 10 Gy IOERT boost prior to WBI provided outstanding local control rates, comparing favorably to all trials with similar length of follow-up.

October 31, 2012

Warenczak-Florczak, Z. et al., “Intraoperative Radiation Therapy as Part of Breast Conserving Therapy of Early Breast Cancer-Results of One-year Follow-up.” (2013)

Treatment Use

Cancer Indication

Number of Patients

60

Summary/Conclusion

IOERT boost during surgery not only enables good local control without geometric miss of the tumor, but also delivers good cosmetic effect after therapy.

October 8, 2012

Forouzannia, A. et al., “Intraoperative Electron Radiotherapy Boost as a Component of Adjuvant Radiation for Breast Cancer in the Community Setting.” (2012)

Treatment Use

Cancer Indication

Number of Patients

50

Summary/Conclusion

IOERT resulted in a reduction of treatment time, was not associated with additional toxicity or change in the acute toxicity profile, and is a feasible treatment option in a community setting.

January 1, 2006

Lemanski, C. et al.,“Intraoperative Radiotherapy Given As A Boost For Early Breast Cancer: Long-term Clinical And Cosmetic Results.” (2006)

Treatment Use

Cancer Indication

Number of Patients

50

Summary/Conclusion

Our results conﬁrm that IORT given as a boost after breast-conserving surgery is a reliable alternative to conventional postoperative fractionated boost radiation.

December 27, 2005

Reitsamer, R. et al., “The Salzburg concept of intraoperative radiotherapy for breast cancer: Results and considerations.” (2006)

Treatment Use

Cancer Indication